首页> 外文期刊>Molecular cancer therapeutics >p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis.
【24h】

p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis.

机译:p27Kip1表达抑制胶质母细胞瘤的生长,侵袭和肿瘤诱导的新血管生成。

获取原文
获取原文并翻译 | 示例
           

摘要

The tumor suppressor gene CDKN1B encodes for a 27-kDa cyclin-dependent kinase inhibitory protein, p27(Kip1), which together with its well-established role in the inhibition of cell proliferation, displays additional activities in the control of gene transcription and cell motility. p27(Kip1) thus represents a good candidate for a gene therapy approach, especially in those cancers refractory to the conventional therapies, like human glioblastoma. Here, we show that overexpression of p27(Kip1) in glioblastoma cell lines induced cell cycle arrest and inhibition of cell motility through extracellular matrix substrates. The use of adenoviral vectors in the treatment of glioblastoma in vivo showed that p27(Kip1) was able to block not only cancer cell growth but also local invasion and tumor-induced neoangiogenesis. The latter effect was due to the ability of p27 to impair both endothelial cell growth and motility, thus preventing proper vessel formation in the tumor. The block of neoangiogenesis depended on cytoplasmic p27(Kip1) antimigratory activity and was linked to its ability to bind to and inhibit the microtubule-destabilizing protein stathmin. Our work provides the first evidence that a successful p27(Kip1)-based gene therapy is linked to tumor microenvironment modification, thus opening new perspectives to the use of gene therapy approaches for the treatment of refractory cancers. [Mol Cancer Ther 2008;7(5):1164-75].
机译:肿瘤抑制基因CDKN1B编码一种27 kDa细胞周期蛋白依赖性激酶抑制蛋白p27(Kip1),其在细胞增殖抑制中的作用已广为人知,在控制基因转录和细胞运动方面显示出额外的活性。 。因此,p27(Kip1)代表了基因治疗方法的良好候选者,特别是在那些对传统疗法如人类胶质母细胞瘤难以治疗的癌症中。在这里,我们显示胶质母细胞瘤细胞系中p27(Kip1)的过度表达诱导细胞周期停滞并通过细胞外基质底物抑制细胞运动。腺病毒载体在体内治疗胶质母细胞瘤中的应用表明p27(Kip1)不仅能够阻止癌细胞的生长,而且能够阻止局部浸润和肿瘤诱导的新血管生成。后一种作用归因于p27破坏内皮细胞生长和运动的能力,从而阻止了肿瘤中正常血管的形成。新生血管生成的阻止取决于细胞质p27(Kip1)的抗迁移活性,并与其绑定和抑制微管破坏性蛋白stathmin的能力有关。我们的工作提供了第一个证据,即基于p27(Kip1)的成功基因治疗与肿瘤微环境修饰相关,从而为使用基因治疗方法治疗难治性癌症开辟了新的前景。 [Mol Cancer Ther 2008; 7(5):1164-75]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号